FDA Drug Recalls

Recalls / Class II

Class IID-0617-2024

Product

Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5mg, packaged in a) 90-count bottles (NDC 68382-034-16) and b)1000-count bottles (NDC 68382-034-10), Rx only, Mfg. by: Zydus Lifesciences Ltd. Ahmedabad, India; Dist. by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534

Brand name
Venlafaxine Hydrochloride
Generic name
Venlafaxine Hydrochloride
Active ingredient
Venlafaxine Hydrochloride
Route
Oral
NDCs
68382-034, 68382-035, 68382-036
FDA application
ANDA090174
Affected lot / code info
Lot #: a) M213175, Exp. Date 09/2024; b) M213176, Exp. Date 09/2024

Why it was recalled

Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at the 8-hour and 12-hour pull intervals.

Recalling firm

Firm
Zydus Pharmaceuticals (USA) Inc
Manufacturer
Zydus Pharmaceuticals USA Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
73 Route 31 N, Pennington, New Jersey 08534-3601

Distribution

Quantity
a) 13,128 bottles; b) 252 bottles
Distribution pattern
Nationwide within the United States

Timeline

Recall initiated
2024-06-21
FDA classified
2024-07-23
Posted by FDA
2024-07-31
Terminated
2025-08-06
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0617-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Venlafaxine Hydrochloride · FDA Drug Recalls